Xellia Pharmaceuticals Expands Into The U.S. With Manufacturing Plant Buy
7/7/2014 7:42:41 AM
Xellia Pharmaceuticals Expands Into The U.S. With Acquisition Of Manufacturing Plant
Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced it has acquired Fresenius Kabi’s dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details are not disclosed.
The manufacturing site is located close to the world famous Research Triangle Park and is Xellia’s first facility in the US, significantly expanding the Company’s manufacturing capacity for injectable pharmaceutical products. Xellia intends to retain all ~80 staff currently employed at the site and will continue to manufacture certain products at the site for Fresenius Kabi. In the future, Xellia plans to employ more staff as it expands the site further.
Commenting on the acquisition, Carl-Åke Carlsson, CEO Xellia said: “This is a great opportunity for us to expand our manufacturing capabilities into the US which is a key market for us. We have great respect for Fresenius Kabi and its employees, and have been in partnership with the company for years as a preferred, trusted supplier of active pharmaceutical ingredients. I believe this acquisition will be a win-win situation, benefiting both companies and our customers.”
“This agreement is part of our global strategy to optimize our manufacturing and supply network,” said John Ducker, president and CEO, Fresenius Kabi USA. “Both companies are committed to assure a smooth and seamless transition for customers and employees. This transaction will have no impact on Fresenius Kabi’s ability to meet customer demand for the products we currently manufacture at the Raleigh site and we continue to work closely with the FDA to alleviate US drug shortages.”
Xellia is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients (APIs) to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage form (FDF) of its drugs. This acquisition is part of the latest phase of Xellia’s on-going global expansion plans which include an investment of $2.0 million at the Company’s Product and Innovation R&D Centre of Excellence in Zagreb, Croatia in May.
- Ends -
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, Hungary and China, and currently employs over 900 people.
Xellia is a leading supplier of Vancomycin and Colistimethate Sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.
Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.
Further information about Xellia can be found at: www.xellia.com.
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The Company’s North America headquarters is in Lake Zurich, Illinois.
In the United States, Fresenius Kabi (www.fresenius-kabi.us) markets a broad portfolio of injectable and specialty pharmaceutical products with a focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets for use in hospitals, long-term care facilities, alternate care sites and clinics.
For more information, please contact:
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00
Instinctif Partners (media relations)
Melanie Toyne Sewell / Eileen Paul / Jen Lewis
Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500
Fresenius Kabi USA (media relations)
Tel: +1 847 220 3033
Help employers find you! Check out all the jobs and post your resume.
comments powered by